25 XP   0   0   10

Finch Therapeutics Group Inc
Buy, Hold or Sell?

Let's analyze Finch Therapeutics Group Inc together

I guess you are interested in Finch Therapeutics Group Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Finch Therapeutics Group Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Finch Therapeutics Group Inc

I send you an email if I find something interesting about Finch Therapeutics Group Inc.

Quick analysis of Finch Therapeutics Group Inc (30 sec.)










What can you expect buying and holding a share of Finch Therapeutics Group Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$11.86
Expected worth in 1 year
$3.19
How sure are you?
5.9%

+ What do you gain per year?

Total Gains per Share
$-8.67
Return On Investment
-641.9%

For what price can you sell your share?

Current Price per Share
$1.35
Expected price per share
$0.8 - $1.87
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Finch Therapeutics Group Inc (5 min.)




Live pricePrice per Share (EOD)

$1.35

Intrinsic Value Per Share

$302.36 - $380.02

Total Value Per Share

$314.22 - $391.88

2. Growth of Finch Therapeutics Group Inc (5 min.)




Is Finch Therapeutics Group Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$19m$102.1m-$78.2m-327.3%

How much money is Finch Therapeutics Group Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4m-$38.2m$34.2m840.5%
Net Profit Margin-26.7%-106,038.5%--

How much money comes from the company's main activities?

3. Financial Health of Finch Therapeutics Group Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Finch Therapeutics Group Inc? (5 min.)

Welcome investor! Finch Therapeutics Group Inc's management wants to use your money to grow the business. In return you get a share of Finch Therapeutics Group Inc.

What can you expect buying and holding a share of Finch Therapeutics Group Inc?

First you should know what it really means to hold a share of Finch Therapeutics Group Inc. And how you can make/lose money.

Speculation

The Price per Share of Finch Therapeutics Group Inc is $1.35. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Finch Therapeutics Group Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Finch Therapeutics Group Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $11.86. Based on the TTM, the Book Value Change Per Share is $-2.17 per quarter. Based on the YOY, the Book Value Change Per Share is $-22.86 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Finch Therapeutics Group Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.41-178.8%-2.54-187.8%-23.73-1,757.9%-10.65-789.0%-10.65-789.0%
Usd Book Value Change Per Share-2.40-177.5%-2.17-160.5%-22.86-1,693.4%0.7051.7%0.7051.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.40-177.5%-2.17-160.5%-22.86-1,693.4%0.7051.7%0.7051.7%
Usd Price Per Share2.60-4.98-1.35-4.91-4.91-
Price to Earnings Ratio-0.27--0.52--0.02--0.23--0.23-
Price-to-Total Gains Ratio-1.09--2.44--0.08--1.21--1.21-
Price to Book Ratio0.22-0.32-0.02-0.11-0.11-
Price-to-Total Gains Ratio-1.09--2.44--0.08--1.21--1.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.35
Number of shares740
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.170.70
Usd Total Gains Per Share-2.170.70
Gains per Quarter (740 shares)-1,603.04516.09
Gains per Year (740 shares)-6,412.162,064.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-6412-6422020642054
20-12824-12834041294118
30-19236-19246061936182
40-25649-25658082578246
50-32061-3207001032210310
60-38473-3848201238612374
70-44885-4489401445014438
80-51297-5130601651516502
90-57709-5771801857918566
100-64122-6413002064320630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%1.013.03.05.9%1.013.03.05.9%1.013.03.05.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%1.013.03.05.9%1.013.03.05.9%1.013.03.05.9%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Finch Therapeutics Group Inc

About Finch Therapeutics Group Inc

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-06-22 06:28:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Finch Therapeutics Group Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Finch Therapeutics Group Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Finch Therapeutics Group Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Finch Therapeutics Group Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-26.7%+26.7%
TTM-26.7%YOY-106,038.5%+106,011.8%
TTM-26.7%5Y-25,686.2%+25,659.5%
5Y-25,686.2%10Y-25,686.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.0%+168.0%
TTM-26.7%-209.9%+183.2%
YOY-106,038.5%-242.3%-105,796.2%
5Y-25,686.2%-401.7%-25,284.5%
10Y-25,686.2%-532.2%-25,154.0%
1.1.2. Return on Assets

Shows how efficient Finch Therapeutics Group Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Finch Therapeutics Group Inc to the Biotechnology industry mean.
  • -7.7% Return on Assets means that Finch Therapeutics Group Inc generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Finch Therapeutics Group Inc:

  • The MRQ is -7.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.7%TTM-6.6%-1.1%
TTM-6.6%YOY-32.1%+25.5%
TTM-6.6%5Y-11.7%+5.1%
5Y-11.7%10Y-11.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.7%-11.9%+4.2%
TTM-6.6%-11.9%+5.3%
YOY-32.1%-11.3%-20.8%
5Y-11.7%-13.5%+1.8%
10Y-11.7%-14.9%+3.2%
1.1.3. Return on Equity

Shows how efficient Finch Therapeutics Group Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Finch Therapeutics Group Inc to the Biotechnology industry mean.
  • -20.4% Return on Equity means Finch Therapeutics Group Inc generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Finch Therapeutics Group Inc:

  • The MRQ is -20.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.4%TTM-17.0%-3.4%
TTM-17.0%YOY-67.3%+50.3%
TTM-17.0%5Y-22.2%+5.2%
5Y-22.2%10Y-22.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.4%-14.2%-6.2%
TTM-17.0%-15.7%-1.3%
YOY-67.3%-14.3%-53.0%
5Y-22.2%-19.2%-3.0%
10Y-22.2%-19.7%-2.5%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Finch Therapeutics Group Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Finch Therapeutics Group Inc is operating .

  • Measures how much profit Finch Therapeutics Group Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Finch Therapeutics Group Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Finch Therapeutics Group Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-41.1%+41.1%
TTM-41.1%YOY-88,687.6%+88,646.4%
TTM-41.1%5Y-21,620.9%+21,579.7%
5Y-21,620.9%10Y-21,620.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--354.6%+354.6%
TTM-41.1%-225.9%+184.8%
YOY-88,687.6%-252.2%-88,435.4%
5Y-21,620.9%-428.3%-21,192.6%
10Y-21,620.9%-531.1%-21,089.8%
1.2.2. Operating Ratio

Measures how efficient Finch Therapeutics Group Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Finch Therapeutics Group Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.411-0.411
TTM0.411YOY1,015.964-1,015.553
TTM0.4115Y247.019-246.607
5Y247.01910Y247.0190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM0.4113.332-2.921
YOY1,015.9643.502+1,012.462
5Y247.0195.271+241.748
10Y247.0196.915+240.104
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Finch Therapeutics Group Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Finch Therapeutics Group Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.05 means the company has $6.05 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Finch Therapeutics Group Inc:

  • The MRQ is 6.052. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.581. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.052TTM5.581+0.471
TTM5.581YOY5.459+0.122
TTM5.5815Y7.220-1.639
5Y7.22010Y7.2200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0523.767+2.285
TTM5.5814.000+1.581
YOY5.4594.905+0.554
5Y7.2205.883+1.337
10Y7.2206.286+0.934
1.3.2. Quick Ratio

Measures if Finch Therapeutics Group Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Finch Therapeutics Group Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.93 means the company can pay off $5.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Finch Therapeutics Group Inc:

  • The MRQ is 5.934. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.385. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.934TTM5.385+0.549
TTM5.385YOY5.273+0.112
TTM5.3855Y6.991-1.606
5Y6.99110Y6.9910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.9343.054+2.880
TTM5.3853.506+1.879
YOY5.2734.756+0.517
5Y6.9915.757+1.234
10Y6.9916.338+0.653
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Finch Therapeutics Group Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Finch Therapeutics Group Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Finch Therapeutics Group Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.62 means that Finch Therapeutics Group Inc assets are financed with 62.0% credit (debt) and the remaining percentage (100% - 62.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Finch Therapeutics Group Inc:

  • The MRQ is 0.620. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.612. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.620TTM0.612+0.008
TTM0.612YOY0.414+0.198
TTM0.6125Y0.362+0.250
5Y0.36210Y0.3620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6200.330+0.290
TTM0.6120.342+0.270
YOY0.4140.287+0.127
5Y0.3620.368-0.006
10Y0.3620.382-0.020
1.4.2. Debt to Equity Ratio

Measures if Finch Therapeutics Group Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Finch Therapeutics Group Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 163.1% means that company has $1.63 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Finch Therapeutics Group Inc:

  • The MRQ is 1.631. The company is just able to pay all its debts with equity.
  • The TTM is 1.609. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.631TTM1.609+0.022
TTM1.609YOY0.773+0.836
TTM1.6095Y0.591+1.018
5Y0.59110Y0.5910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6310.365+1.266
TTM1.6090.415+1.194
YOY0.7730.370+0.403
5Y0.5910.443+0.148
10Y0.5910.476+0.115
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Finch Therapeutics Group Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Finch Therapeutics Group Inc generates.

  • Above 15 is considered overpriced but always compare Finch Therapeutics Group Inc to the Biotechnology industry mean.
  • A PE ratio of -0.27 means the investor is paying $-0.27 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Finch Therapeutics Group Inc:

  • The EOD is -0.140. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.269. Based on the earnings, the company is expensive. -2
  • The TTM is -0.525. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.140MRQ-0.269+0.129
MRQ-0.269TTM-0.525+0.256
TTM-0.525YOY-0.019-0.506
TTM-0.5255Y-0.225-0.300
5Y-0.22510Y-0.2250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.140-2.341+2.201
MRQ-0.269-2.997+2.728
TTM-0.525-2.882+2.357
YOY-0.019-3.553+3.534
5Y-0.225-6.262+6.037
10Y-0.225-6.288+6.063
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Finch Therapeutics Group Inc:

  • The EOD is -0.124. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.239. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.350. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.124MRQ-0.239+0.115
MRQ-0.239TTM-0.350+0.111
TTM-0.350YOY-0.032-0.318
TTM-0.3505Y-0.156-0.194
5Y-0.15610Y-0.1560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.124-2.932+2.808
MRQ-0.239-3.739+3.500
TTM-0.350-3.776+3.426
YOY-0.032-4.917+4.885
5Y-0.156-7.942+7.786
10Y-0.156-8.503+8.347
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Finch Therapeutics Group Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.22 means the investor is paying $0.22 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Finch Therapeutics Group Inc:

  • The EOD is 0.114. Based on the equity, the company is cheap. +2
  • The MRQ is 0.219. Based on the equity, the company is cheap. +2
  • The TTM is 0.321. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.114MRQ0.219-0.105
MRQ0.219TTM0.321-0.102
TTM0.321YOY0.020+0.302
TTM0.3215Y0.105+0.216
5Y0.10510Y0.1050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.1141.843-1.729
MRQ0.2192.249-2.030
TTM0.3212.301-1.980
YOY0.0202.412-2.392
5Y0.1053.782-3.677
10Y0.1054.212-4.107
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Finch Therapeutics Group Inc.

3.1. Institutions holding Finch Therapeutics Group Inc

Institutions are holding 11.353% of the shares of Finch Therapeutics Group Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Susquehanna International Group, LLP3.67605902800
2024-03-31Vanguard Group Inc2.2576036252-2512-6.4802
2023-12-31Renaissance Technologies Corp0.73150.000111746117460
2024-03-31Ikarian Capital, LLC0.42920.002689200
2023-12-31Tower Research Capital LLC0.16350.000126262187498.1777
2024-03-31Bleichroeder LP0.06050.000697100
2023-12-31BlackRock Inc0.0212034100
2023-12-31Northwestern Mutual Wealth Management Co0.008801411410
2023-12-31Morgan Stanley - Brokerage Accounts0.0077012300
2023-12-31Royal Bank of Canada0.001702700
2023-12-31Bank of America Corp0.0007012120
2023-12-31Wells Fargo & Co0.00040600
2023-12-31Moisand Fitzgerald Tamayo, LLC0.00020300
2023-12-31Cutler Group LP0.00020300
2023-12-31UBS Group AG0.00010200
2023-12-31MSD Partners, L.P.000-5113-100
2023-12-31LAKE STREET ADVISORS GROUP, LLC000-21206-100
2023-12-31Ancora Advisors LLC000-533-100
2023-12-31Steward Partners Investment Advisory, LLC000-75-100
2024-03-31Baupost Group LLC000-67296-100
Total 7.35930.0028118173-82649-69.9%

3.2. Funds holding Finch Therapeutics Group Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr1.01101623400
2024-04-30Vanguard Total Stock Mkt Idx Inv0.604509707-10311-51.5086
2023-12-31Greenwich Ivy Long-Short Instl0.46690.1113749700
2024-03-31Fidelity Extended Market Index0.23120371300
2024-03-31Fidelity Total Market Index0.10010160700
2024-03-31Fidelity Nasdaq Composite Index0.0529084900
2024-03-31Northern Trust Extended Eq Market Idx0.0356057100
2024-03-31NT Ext Equity Mkt Idx Fd - L0.0356057100
2024-03-31Spartan Total Market Index Pool E0.0301048400
2024-03-31NT Ext Equity Mkt Idx Fd - NL0.0149024000
2024-03-31Fidelity Series Total Market Index0.0145023300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.012019300
2024-04-30State St US Extended Mkt Indx NL Cl C0.0066010600
2023-12-31SSgA U.S. Extended Market Index Class I0.0066010600
2023-12-31SSgA U.S. Total Market Index Strategy0.0019031-1-3.125
2024-04-30State St US Ttl Mkt Indx SL Cl I0.001903000
2024-03-31Northern Trust Wilshire 50000.001702700
2023-12-31NT US Market Cap Idx Fd - L0.001702700
2024-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.001402315187.5
2023-09-30BlackRock Extended Mkt Composite0.000901400
Total 2.6320.111342263-10297-24.4%

3.3. Insider Transactions

Insiders are holding 53.457% of the shares of Finch Therapeutics Group Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-28Jeffery A. SmisekSELL66422.57
2023-11-22Jeffery A SmisekSELL14703.64
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Finch Therapeutics Group Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.396-2.166-10%-22.861+854%0.697-444%0.697-444%
Book Value Per Share--11.85614.889-20%63.618-81%54.143-78%54.143-78%
Current Ratio--6.0525.581+8%5.459+11%7.220-16%7.220-16%
Debt To Asset Ratio--0.6200.612+1%0.414+50%0.362+71%0.362+71%
Debt To Equity Ratio--1.6311.609+1%0.773+111%0.591+176%0.591+176%
Dividend Per Share----0%-0%-0%-0%
Eps---2.414-2.535+5%-23.731+883%-10.652+341%-10.652+341%
Free Cash Flow Per Share---2.716-3.499+29%-9.944+266%-8.425+210%-8.425+210%
Free Cash Flow To Equity Per Share---2.716-3.498+29%-10.145+273%-0.757-72%-0.757-72%
Gross Profit Margin--1.0111.006+0%1.000+1%1.002+1%1.002+1%
Intrinsic Value_10Y_max--380.024--------
Intrinsic Value_10Y_min--302.363--------
Intrinsic Value_1Y_max---25.053--------
Intrinsic Value_1Y_min---24.646--------
Intrinsic Value_3Y_max---27.159--------
Intrinsic Value_3Y_min---26.900--------
Intrinsic Value_5Y_max--28.743--------
Intrinsic Value_5Y_min--22.537--------
Market Cap2167776.000-93%4175144.3767996729.602-48%2160951.520+93%7889298.334-47%7889298.334-47%
Net Profit Margin----0.2670%-1060.3850%-256.8620%-256.8620%
Operating Margin----0.4110%-886.8760%-216.2090%-216.2090%
Operating Ratio---0.411-100%1015.964-100%247.019-100%247.019-100%
Pb Ratio0.114-93%0.2190.321-32%0.020+1024%0.105+108%0.105+108%
Pe Ratio-0.140+48%-0.269-0.525+95%-0.019-93%-0.225-16%-0.225-16%
Price Per Share1.350-93%2.6004.980-48%1.346+93%4.913-47%4.913-47%
Price To Free Cash Flow Ratio-0.124+48%-0.239-0.350+46%-0.032-87%-0.156-35%-0.156-35%
Price To Total Gains Ratio-0.563+48%-1.085-2.443+125%-0.083-92%-1.214+12%-1.214+12%
Quick Ratio--5.9345.385+10%5.273+13%6.991-15%6.991-15%
Return On Assets---0.077-0.066-14%-0.321+315%-0.117+51%-0.117+51%
Return On Equity---0.204-0.170-17%-0.673+230%-0.222+9%-0.222+9%
Total Gains Per Share---2.396-2.166-10%-22.861+854%0.697-444%0.697-444%
Usd Book Value--19038000.00023907750.000-20%102155250.000-81%86941176.471-78%86941176.471-78%
Usd Book Value Change Per Share---2.396-2.166-10%-22.861+854%0.697-444%0.697-444%
Usd Book Value Per Share--11.85614.889-20%63.618-81%54.143-78%54.143-78%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.414-2.535+5%-23.731+883%-10.652+341%-10.652+341%
Usd Free Cash Flow---4362000.000-5618000.000+29%-15968250.000+266%-13528117.647+210%-13528117.647+210%
Usd Free Cash Flow Per Share---2.716-3.499+29%-9.944+266%-8.425+210%-8.425+210%
Usd Free Cash Flow To Equity Per Share---2.716-3.498+29%-10.145+273%-0.757-72%-0.757-72%
Usd Market Cap2167776.000-93%4175144.3767996729.602-48%2160951.520+93%7889298.334-47%7889298.334-47%
Usd Price Per Share1.350-93%2.6004.980-48%1.346+93%4.913-47%4.913-47%
Usd Profit---3876000.000-4070750.000+5%-38285500.000+888%-17145882.353+342%-17145882.353+342%
Usd Revenue---711250.000-100%153500.000-100%1768470.588-100%1768470.588-100%
Usd Total Gains Per Share---2.396-2.166-10%-22.861+854%0.697-444%0.697-444%
 EOD+3 -5MRQTTM+15 -17YOY+23 -95Y+14 -1810Y+14 -18

4.2. Fundamental Score

Let's check the fundamental score of Finch Therapeutics Group Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.140
Price to Book Ratio (EOD)Between0-10.114
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.934
Current Ratio (MRQ)Greater than16.052
Debt to Asset Ratio (MRQ)Less than10.620
Debt to Equity Ratio (MRQ)Less than11.631
Return on Equity (MRQ)Greater than0.15-0.204
Return on Assets (MRQ)Greater than0.05-0.077
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Finch Therapeutics Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.815
Ma 20Greater thanMa 501.366
Ma 50Greater thanMa 1001.760
Ma 100Greater thanMa 2002.153
OpenGreater thanClose1.220
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-03-312023-06-302023-09-302023-12-312024-03-31
Long-term Assets Other  1,9134052,318302,34802,348-2,3480



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets50,092
Total Liabilities31,054
Total Stockholder Equity19,038
 As reported
Total Liabilities 31,054
Total Stockholder Equity+ 19,038
Total Assets = 50,092

Assets

Total Assets50,092
Total Current Assets21,175
Long-term Assets28,917
Total Current Assets
Cash And Cash Equivalents 20,762
Other Current Assets 413
Total Current Assets  (as reported)21,175
Total Current Assets  (calculated)21,175
+/-0
Long-term Assets
Property Plant Equipment 26,569
Other Assets 0
Long-term Assets  (as reported)28,917
Long-term Assets  (calculated)26,569
+/- 2,348

Liabilities & Shareholders' Equity

Total Current Liabilities3,499
Long-term Liabilities27,555
Total Stockholder Equity19,038
Total Current Liabilities
Short-term Debt 2,008
Accounts payable 47
Other Current Liabilities 1,444
Total Current Liabilities  (as reported)3,499
Total Current Liabilities  (calculated)3,499
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt27,555
Long-term Liabilities  (as reported)27,555
Long-term Liabilities  (calculated)27,555
+/-0
Total Stockholder Equity
Common Stock2
Retained Earnings -354,271
Other Stockholders Equity 373,307
Total Stockholder Equity (as reported)19,038
Total Stockholder Equity (calculated)19,038
+/-0
Other
Capital Stock2
Cash and Short Term Investments 20,762
Common Stock Shares Outstanding 1,606
Liabilities and Stockholders Equity 50,092
Net Debt 8,801
Net Invested Capital 19,038
Net Working Capital 17,676
Property Plant and Equipment Gross 26,869
Short Long Term Debt Total 29,563



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
165,338
265,951
250,328
232,979
225,369
204,633
228,301
187,968
162,939
79,040
66,857
59,493
70,997
50,092
50,09270,99759,49366,85779,040162,939187,968228,301204,633225,369232,979250,328265,951165,338000
   > Total Current Assets 
0
0
0
106,164
193,023
177,003
156,167
133,481
122,649
110,545
90,616
71,038
41,684
36,499
29,919
25,847
21,175
21,17525,84729,91936,49941,68471,03890,616110,545122,649133,481156,167177,003193,023106,164000
       Cash And Cash Equivalents 
0
0
0
99,710
193,023
168,136
149,200
133,481
106,931
104,673
85,292
71,038
41,684
34,051
28,779
25,124
20,762
20,76225,12428,77934,05141,68471,03885,292104,673106,931133,481149,200168,136193,02399,710000
       Net Receivables 
0
0
0
1,095
2,303
2,250
2,399
494
172
174
0
144
107
0
0
0
0
000010714401741724942,3992,2502,3031,095000
       Other Current Assets 
0
0
0
5,359
3,015
6,617
4,568
8,576
15,546
5,698
5,324
3,369
1,606
2,448
1,140
723
413
4137231,1402,4481,6063,3695,3245,69815,5468,5764,5686,6173,0155,359000
   > Long-term Assets 
0
0
0
59,174
72,928
73,325
76,812
91,888
81,984
117,756
97,352
91,901
37,356
30,358
29,574
45,150
28,917
28,91745,15029,57430,35837,35691,90197,352117,75681,98491,88876,81273,32572,92859,174000
       Property Plant Equipment 
0
0
0
7,004
16,438
18,327
19,546
24,688
24,217
59,634
57,635
48,688
33,075
28,040
27,226
27,178
26,569
26,56927,17827,22628,04033,07548,68857,63559,63424,21724,68819,54618,32716,4387,004000
       Goodwill 
0
0
0
18,057
18,057
18,057
18,057
18,057
18,057
18,057
0
0
0
0
0
0
0
000000018,05718,05718,05718,05718,05718,05718,057000
       Intangible Assets 
0
0
0
32,900
32,900
32,900
32,900
32,900
32,900
32,900
32,900
32,900
0
0
0
0
0
0000032,90032,90032,90032,90032,90032,90032,90032,90032,900000
       Other Assets 
0
0
0
0
33,116
82,192
83,779
40,073
39,710
123,628
39,717
39,700
0
2,318
0
0
0
0002,318039,70039,717123,62839,71040,07383,77982,19233,1160000
> Total Liabilities 
0
0
0
261,056
26,494
22,135
13,178
23,145
24,842
69,209
67,102
67,228
46,088
38,963
33,680
48,111
31,054
31,05448,11133,68038,96346,08867,22867,10269,20924,84223,14513,17822,13526,494261,056000
   > Total Current Liabilities 
0
0
0
11,486
11,503
9,524
8,851
14,790
16,787
15,183
13,808
14,689
13,206
9,575
4,879
4,084
3,499
3,4994,0844,8799,57513,20614,68913,80815,18316,78714,7908,8519,52411,50311,486000
       Short-term Debt 
0
0
0
0
0
0
0
1,128
1,148
4,755
2,641
3,431
3,253
1,656
1,971
1,723
2,008
2,0081,7231,9711,6563,2533,4312,6414,7551,1481,1280000000
       Accounts payable 
0
0
0
2,621
3,878
1,719
1,382
3,737
4,765
1,013
1,060
1,097
2,553
432
357
141
47
471413574322,5531,0971,0601,0134,7653,7371,3821,7193,8782,621000
       Other Current Liabilities 
0
0
0
5,494
4,994
5,230
7,469
9,925
10,874
9,415
10,107
10,161
7,400
7,487
2,551
2,220
1,444
1,4442,2202,5517,4877,40010,16110,1079,41510,8749,9257,4695,2304,9945,494000
   > Long-term Liabilities 
0
0
0
249,570
26,494
12,611
4,327
23,145
8,055
54,026
53,294
67,228
46,088
29,388
28,801
44,027
27,555
27,55544,02728,80129,38846,08867,22853,29454,0268,05523,1454,32712,61126,494249,570000
       Long term Debt Total 
0
0
0
0
1,808
0
0
0
0
14,620
0
0
0
0
0
0
0
000000014,62000001,8080000
       Other Liabilities 
0
0
0
0
13,183
22,135
13,178
3,461
3,461
69,209
3,586
3,631
0
0
0
0
0
000003,6313,58669,2093,4613,46113,17822,13513,1830000
       Deferred Long Term Liability 
0
0
0
0
32,900
32,900
4,153
32,900
3,461
3,461
32,900
32,900
0
0
0
0
0
0000032,90032,9003,4613,46132,9004,15332,90032,9000000
> Total Stockholder Equity
0
0
0
-95,718
239,457
228,193
219,801
202,224
179,791
159,092
120,866
95,711
32,952
27,894
25,813
22,886
19,038
19,03822,88625,81327,89432,95295,711120,866159,092179,791202,224219,801228,193239,457-95,718000
   Common Stock
0
0
0
8
47
47
47
47
48
48
48
48
48
2
2
2
2
22224848484848474747478000
   Retained Earnings Total Equity0000000-208,262-185,5620-141,940-131,985-116,8160000
   Accumulated Other Comprehensive Income 0000000000-232,979-250,328-265,9510000
   Capital Surplus 
0
0
0
0
356,226
360,131
361,694
0
365,305
367,306
0
0
0
0
0
0
0
0000000367,306365,3050361,694360,131356,2260000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
0
0
0
7,109
356,226
360,131
361,694
363,172
365,305
367,306
369,451
371,304
372,484
372,830
373,165
373,279
373,307
373,307373,279373,165372,830372,484371,304369,451367,306365,305363,172361,694360,131356,2267,109000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue107
Cost of Revenue-1,520
Gross Profit-1,413-1,413
 
Operating Income (+$)
Gross Profit-1,413
Operating Expense-32,589
Operating Income-34,002-34,002
 
Operating Expense (+$)
Research Development5,679
Selling General Administrative26,910
Selling And Marketing Expenses0
Operating Expense32,58932,589
 
Net Interest Income (+$)
Interest Income1,570
Interest Expense-0
Other Finance Cost-74
Net Interest Income1,496
 
Pretax Income (+$)
Operating Income-34,002
Net Interest Income1,496
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-78,21510,211
EBIT - interestExpense = -34,002
-78,215
-74,754
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-34,002-78,215
Earnings Before Interest and Taxes (EBITDA)-32,482
 
After tax Income (+$)
Income Before Tax-78,215
Tax Provision--3,461
Net Income From Continuing Ops-98,721-74,754
Net Income-74,754
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses34,109
Total Other Income/Expenses Net-44,213-1,496
 

Technical Analysis of Finch Therapeutics Group Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Finch Therapeutics Group Inc. The general trend of Finch Therapeutics Group Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Finch Therapeutics Group Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Finch Therapeutics Group Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.55 < 1.86 < 1.87.

The bearish price targets are: 0.8.

Tweet this
Finch Therapeutics Group Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Finch Therapeutics Group Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Finch Therapeutics Group Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Finch Therapeutics Group Inc. The current macd is -0.10589941.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Finch Therapeutics Group Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Finch Therapeutics Group Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Finch Therapeutics Group Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Finch Therapeutics Group Inc Daily Moving Average Convergence/Divergence (MACD) ChartFinch Therapeutics Group Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Finch Therapeutics Group Inc. The current adx is 14.79.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Finch Therapeutics Group Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Finch Therapeutics Group Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Finch Therapeutics Group Inc. The current sar is 1.8536.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Finch Therapeutics Group Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Finch Therapeutics Group Inc. The current rsi is 44.82. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Finch Therapeutics Group Inc Daily Relative Strength Index (RSI) ChartFinch Therapeutics Group Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Finch Therapeutics Group Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Finch Therapeutics Group Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Finch Therapeutics Group Inc Daily Stochastic Oscillator ChartFinch Therapeutics Group Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Finch Therapeutics Group Inc. The current cci is -62.71669958.

Finch Therapeutics Group Inc Daily Commodity Channel Index (CCI) ChartFinch Therapeutics Group Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Finch Therapeutics Group Inc. The current cmo is -6.43118892.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Finch Therapeutics Group Inc Daily Chande Momentum Oscillator (CMO) ChartFinch Therapeutics Group Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Finch Therapeutics Group Inc. The current willr is -68.75.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Finch Therapeutics Group Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Finch Therapeutics Group Inc Daily Williams %R ChartFinch Therapeutics Group Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Finch Therapeutics Group Inc.

Finch Therapeutics Group Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Finch Therapeutics Group Inc. The current atr is 0.22609496.

Finch Therapeutics Group Inc Daily Average True Range (ATR) ChartFinch Therapeutics Group Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Finch Therapeutics Group Inc. The current obv is 534,983.

Finch Therapeutics Group Inc Daily On-Balance Volume (OBV) ChartFinch Therapeutics Group Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Finch Therapeutics Group Inc. The current mfi is 65.92.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Finch Therapeutics Group Inc Daily Money Flow Index (MFI) ChartFinch Therapeutics Group Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Finch Therapeutics Group Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-05-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-05-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-28STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Finch Therapeutics Group Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Finch Therapeutics Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.815
Ma 20Greater thanMa 501.366
Ma 50Greater thanMa 1001.760
Ma 100Greater thanMa 2002.153
OpenGreater thanClose1.220
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Finch Therapeutics Group Inc with someone you think should read this too:
  • Are you bullish or bearish on Finch Therapeutics Group Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Finch Therapeutics Group Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Finch Therapeutics Group Inc

I send you an email if I find something interesting about Finch Therapeutics Group Inc.


Stay informed about Finch Therapeutics Group Inc.

Receive notifications about Finch Therapeutics Group Inc in your mailbox!